SUPN:NSD-Supernus Pharmaceuticals Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | NASDAQ Global Market

Last Closing

USD 33.52

Change

-6.23 (-15.67)%

Market Cap

USD 1.05B

Volume

2.22M

Analyst Target

USD 29.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-19 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+1.85 (+1.62%)

USD 15.37B
ITCI Intracellular Th

-0.06 (-0.05%)

USD 13.50B
VTRS Viatris Inc

+0.13 (+1.19%)

USD 13.01B
LNTH Lantheus Holdings Inc

-0.55 (-0.68%)

USD 6.78B
ALKS Alkermes Plc

-0.34 (-0.95%)

USD 5.10B
ALVO Alvotech

-0.02 (-0.17%)

USD 3.84B
HCM HUTCHMED DRC

+0.50 (+3.37%)

USD 2.39B
AMPH Amphastar P

+0.09 (+0.29%)

USD 1.75B
DVAX Dynavax Technologies Corporati..

+0.24 (+1.83%)

USD 1.69B
EVO Evotec SE ADR

+0.04 (+0.90%)

USD 1.65B

ETFs Containing SUPN

IBRN iShares Trust - iShares N.. 4.19 % 0.00 %

+0.12 (+0.48%)

USD 3.90M
ETLI:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.30% 49% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.30% 49% F 27% F
Trailing 12 Months  
Capital Gain 19.12% 76% C+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.12% 75% C 68% D+
Trailing 5 Years  
Capital Gain 39.72% 80% B- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.72% 80% B- 65% D
Average Annual (5 Year Horizon)  
Capital Gain 12.32% 54% F 65% D
Dividend Return 12.32% 54% F 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.73% 90% A- 71% C-
Risk Adjusted Return 51.91% 88% B+ 78% C+
Market Capitalization 1.05B 90% A- 79% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 47.30 50% 27%
Price/Book Ratio 2.12 55% 48%
Price / Cash Flow Ratio 19.16 17% 17%
Price/Free Cash Flow Ratio 11.36 28% 33%
Management Effectiveness  
Return on Equity 6.22% 85% 69%
Return on Invested Capital -0.61% 73% 55%
Return on Assets 2.89% 81% 77%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector